This article was originally published in The Gray Sheet
Two-for-one stock split effective Sept. 24 will apply to shareholders of record Sept. 10. The distribution represents the tenth two-for-one split since the firm's initial public offering in 1960 at $1.75 per share
You may also be interested in...
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.
As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.
Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.